Orrick Represents Japan's Nitto in Acquisition of Two U.S. Biopharma Companies


Orrick represented Nitto Denko Corporation (Nitto), a Japanese industrial and technology conglomerate, and its subsidiary, Nitto Denko Avecia Inc. (Avecia), in their acquisition of Irvine Pharmaceutical Services, Inc. (IPS) and Avrio Biopharmaceuticals, LLC (Avrio). Avecia plans to consolidate the purchased assets into a newly established company, Nitto Avecia Pharma Services, Inc. (Pharma Services).

IPS provides pharmaceutical, biopharmaceutical and medical device analytical services, including analytical methods development, chemical testing, microbiology testing, stability services, structural chemistry, drug delivery device technologies, and biopharmaceutical development and testing.

Avrio provides aseptic contract manufacturing services, including pre-formulation development, formulation development, clinical and commercial “sterile fill and finish” and lyophilization manufacturing.

The acquisition of the businesses of IPS and Avrio through Pharma Services will bolster Avecia’s analytical capabilities and complement its existing oligonucleotide drug substance development, production and commercialization services.

Established in 1918, Nitto, led by President, CEO and COO Hideo Takasaki, is currently expanding its businesses as a global market leader across several industries, including electronics, automotive, housing, infrastructure, environmental, and medical sectors, operating through over 100 companies worldwide with over 30,000 employees.

The Orrick team advising Nitto was led by Hiroshi Sarumida, with support from Jesse Infeld, Brian Blood, Andrew Berman, Jean Luyat, James McQuade, Mitch Pahl, John Narducci, Jamie Larkin, Bob Lawrence and Zach Huey.